Tissue specific prodrugs

Details Tissue specific prodrugs Tissue specific prodrugs

2001-11-30

2008-12-23

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07468354

ABSTRACT:
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic drug are activated and exert their toxicity. Sesquiterpene-γ-lactones form part of the prodrugs, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.

REFERENCES:
patent: WO 98/03873 (1998-01-01), None
patent: WO 98/52966 (1998-11-01), None
patent: WO 01/62300 (2001-08-01), None
patent: WO 02/22833 (2002-03-01), None
patent: WO 02/098885 (2002-12-01), None
Nielson et al. “Structure-activity relationships of analogues of thapsigargin modified at O-11 and O-12,” J. Med. Chem., 1995, 38, 272.
Pangalos et al. “Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated a-linked acidic dipeptidase and didpeptidyl peptidase IV activity,” J. Biol. Chem., 1999, 274, 8470.
Knox et al. “Prodrugs in cancer therapy,” Path. Onc. Res., 1997, 3, 309.
Carter et al. “Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase,” Proc. Natl. Acad. Sci. USA, 1996, 93, 749-53.
Pinto et al. “Prostate Specific Membrane Antigen, a Unique Glutamate Carboxypeptidase: A Review of Recent Findings.” The Prostate Journal., 1999, 1, 15-26.
Denmeade et al. “Specific and Efficient Peptide Substrates for Assaying the Proteolytic Activity of Prostate-specific Antigen” Cancer Research, 1997, 57, 4924-30.
N.D. Rawlings, et al. “Structure of Membrane Glutamate Carboxypeptidase”, Biochimica et Biophysica Acta vol. 1339, No. 2, 1997 pp. 247-252.
W.D. Heston, “Characterization and Glutamyl Preferring Caboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase” Urology. United States Mar. 1997 vol. 49, No. 3a pp. 104-112.
Y.Z. Grasso, et al., “Prostate-Specific Membrane Antigen as a Target for Prodrug Therapy: Relationship Between it Folate Hydrolase and Endocytosis Activities” Proceedings of the American Associate For Cancer Research Annual, vol. 42 Mar. 2001, p. 777.

Affiliated with

Also associated with

Rating

Tissue specific prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tissue specific prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue specific prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4021570